Working… Menu

Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00694330
Recruitment Status : Completed
First Posted : June 10, 2008
Last Update Posted : June 22, 2017
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Information provided by (Responsible Party):
William T. Curry, MD, Massachusetts General Hospital

Brief Summary:
This research study is testing the safety of a vaccination of cells called GM-K562 cells mixed with the participants own irradiated tumor cells. The GM-K562 cells have been modified in the laboratory to secrete the protein GM-CSF. This protein can be effective in stimulating an immune response to cancer. This newly developed vaccine may stop cancer cells from growing.

Condition or disease Intervention/treatment Phase
Glioma Biological: GM-K562 Vaccination Phase 1

Detailed Description:
  • Participants will undergo a craniotomy (brain surgery) to remove as much of the tumor as possible from their brain. A pathologist will examine the tissue to determine whether the cells are viable. If not, we will not be able to make the vaccine and the participant will not be eligible to proceed with this treatment protocol.
  • The dose of the vaccine will be determined by the number of tumor cells that we are able to collect from the surgery. We will also be trying to determine the appropriate number of GM-K562 cells that can be given safely. We will do this by assigning groups of participants to different dose levels of GM-K562.
  • For the first three weeks of this study, vaccines will be given once each week. After the first three weeks, vaccines will be given every other week.
  • Before the first and after the fourth vaccinations, a small amount of the participants own irradiated tumor cells will be injected under their skin to see if their immune system will react against it. If the participant develops a rash, they may be asked to undergo a small skin biopsy for additional evaluation. These biopsies are optional.
  • During the course of the study, we will also be collecting blood samples to evaluate the effect that the vaccinations may have on the immune system. These tests will be done every month.
  • Participants will have an MRI once every two months.
  • The following tests and procedures will be done before the participant receive the vaccine and every two weeks (During the first month, these will be performed on Days 1, 3 or 4, 15, 29 and 31 or 32): medical history; physical exam; vital signs; neurological exam; routine blood tests; research blood tests.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor
Actual Study Start Date : June 2008
Actual Primary Completion Date : August 2009
Actual Study Completion Date : August 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: GM-K562 Vaccination Biological: GM-K562 Vaccination
Lethally irradiated autologous glioma cells combined with GM-K562 cells as vaccine therapy given once a week for three weeks then every other week.

Primary Outcome Measures :
  1. To determine the feasibility of preparing lethally irradiated autologous glioma cells for use in combination with irradiated GM-K562 cells as vaccination therapy in this patient population. [ Time Frame: 3 years ]
  2. To determine the safety and biological activity of subcutaneous and intradermal injection of irradiated autologous malignant glioma cells mixed with irradiated GM-CSF producing GM-K562 cells in this patient population. [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Progression free survival [ Time Frame: 3 years ]
  2. overall survival [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have recurrent malignant glioma, having already been diagnosed with and treated for biopsy-proven glioblastoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma or gliosarcoma.
  • Patients will already have been treated with external beam irradiation with or without chemotherapy.
  • Patients must be able to undergo a MRI.
  • A priori clinical indication for open resection/debulking of recurrent malignant glioma.
  • At the time of vaccination, patients must be at least 4 weeks from completion of radiotherapy and 4 weeks from cytotoxic chemotherapy.
  • Serum absolute neutrophil count greater than or equal to 1500/mm3
  • Serum platelets greater than or equal to 50,000/mm3
  • Serum sodium greater than or equal to 125 mmol/L
  • 18 years of age or older
  • Karnofsky Performance Score of 60% or greater

Exclusion Criteria:

  • Uncontrolled active infection
  • Pregnancy or nursing mothers
  • HIV infection
  • Evidence of active infection with Hepatitis B or C
  • Concurrent malignancy
  • Active or clinically relevant autoimmune disease
  • Urgent need for surgical decompression (at the time of initial consultation)
  • Previous participation in a gene therapy or immunotherapy trial
  • Inability to provide informed consent because of altered mental status or mental illness
  • Any other medical, surgical or psychiatric condition which could interfere with the patient's inability to comply with protocol regimen

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00694330

Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Massachusetts General Hospital
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Layout table for investigator information
Principal Investigator: William Curry, MD Massachusetts General Hospital
Layout table for additonal information
Responsible Party: William T. Curry, MD, Principal Investigator, Massachusetts General Hospital Identifier: NCT00694330    
Other Study ID Numbers: 06-349
First Posted: June 10, 2008    Key Record Dates
Last Update Posted: June 22, 2017
Last Verified: March 2017
Keywords provided by William T. Curry, MD, Massachusetts General Hospital:
malignant glioma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Disease Attributes
Pathologic Processes
Immunologic Factors
Physiological Effects of Drugs